Dimensional Fund Advisors LP Boosts Stock Position in MiMedx Group, Inc. (NASDAQ:MDXG)

Dimensional Fund Advisors LP lifted its position in MiMedx Group, Inc. (NASDAQ:MDXG) by 47.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,292,822 shares of the company’s stock after buying an additional 413,443 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.88% of MiMedx Group worth $8,958,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of MDXG. Harbor Capital Advisors Inc. purchased a new stake in shares of MiMedx Group in the 2nd quarter valued at $1,781,000. Cannell Capital LLC increased its holdings in MiMedx Group by 9.1% during the 4th quarter. Cannell Capital LLC now owns 2,480,969 shares of the company’s stock worth $21,758,000 after purchasing an additional 207,207 shares during the period. Los Angeles Capital Management LLC purchased a new stake in MiMedx Group during the 2nd quarter worth about $988,000. Caxton Associates LP purchased a new stake in MiMedx Group during the 1st quarter worth about $1,018,000. Finally, Victory Capital Management Inc. increased its holdings in MiMedx Group by 909.0% during the 2nd quarter. Victory Capital Management Inc. now owns 138,449 shares of the company’s stock worth $959,000 after purchasing an additional 124,727 shares during the period. Hedge funds and other institutional investors own 79.15% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have weighed in on MDXG. Cantor Fitzgerald restated an “overweight” rating and set a $11.00 price target on shares of MiMedx Group in a report on Thursday, August 1st. Craig Hallum lowered their price objective on MiMedx Group from $14.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, August 1st. Finally, StockNews.com raised MiMedx Group from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, September 4th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, MiMedx Group has a consensus rating of “Buy” and an average target price of $12.00.

MiMedx Group Trading Down 2.6 %

NASDAQ:MDXG opened at $5.61 on Tuesday. The stock has a market cap of $828.06 million, a P/E ratio of 12.75 and a beta of 1.97. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.22 and a current ratio of 3.85. MiMedx Group, Inc. has a 1 year low of $5.57 and a 1 year high of $9.27. The stock has a 50-day simple moving average of $6.36 and a 200-day simple moving average of $6.85.

MiMedx Group (NASDAQ:MDXG) last announced its earnings results on Wednesday, July 31st. The company reported $0.08 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.08. The firm had revenue of $87.21 million during the quarter, compared to analysts’ expectations of $88.44 million. MiMedx Group had a return on equity of 34.24% and a net margin of 23.63%. As a group, analysts anticipate that MiMedx Group, Inc. will post 0.26 earnings per share for the current fiscal year.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.